Drugs/Safety Alert·FDA MedWatch Safety Alerts

Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP

MediumPublished Jun 12, 2026· AI-analyzed Jun 12, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Medline is initiating a correction for specific convenience kits to remove Huons Bupivacaine Hydrochloride in Dextrose Injection components that were subject to a prior recall.

Who it affects

This affects Medline, healthcare facilities utilizing these specific convenience kits, and procurement departments responsible for managing surgical or anesthetic kit inventory.

Why it matters

This action highlights the regulatory risks associated with convenience kits where a recall of a single component necessitates an intervention for the entire finished package. It suggests that kit assemblers must maintain robust tracking systems to effectively execute field corrections when component-level safety issues arise.

Practical takeaway

QA and supply chain teams should immediately identify and sequester affected convenience kits to facilitate the removal of the recalled Huons Bupivacaine components as instructed by the manufacturer.

FDA source material

Medline is correcting affected convenience kits by removing recalled Bupivacaine Hydrochloride in Dextrose Injection components.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.